CRYABhom	
    			    			
                UKEi001-A-1            
            
        General
Donor Information
| General Donor Information | |
| Sex | female | 
| Phenotype and Disease related information (Donor) | |
| Diseases | No disease was diagnosed. | 
| Disease associated phenotypes | no phenotypes | 
| Family history | None | 
| Is the medical history available upon request? | On request | 
| Is clinical information available? | On request. Healthy heart (MRI, echocardiography). | 
| Karyotyping (Donor) | |
| Has the donor karyotype been analysed? | Unknown | 
| Other Genotyping (Donor) | |
| Is there genome-wide genotyping or functional data available? | Yes 
										Illumina TruSight Cardio Sequencing Kit.										
																				
										 No pathogenic or likely pathogenic variants detected | 
| Donor Relations | |
| Other cell lines of this donor | |
| External Databases (Donor) | |
| BioSamples | SAMEA6235103 | 
Ethics
Also have a look at the ethics information for the parental line
        				
		
			UKEi001-A		
        				.
        			        
        			        			        			        			| Is there an MTA available for the cell line? | No | 
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | IDT | 
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No | 
hIPSC Derivation
| General | |
| The source cell information can be found in the parental cell line
						UKEi001-A. | |
| Passage number reprogrammed | 29 | 
| Reprogramming method | |
| Vector type | Non-integrating | 
| Vector | Sendai virus | 
| Is reprogramming vector detectable? | No | 
| Methods used | 
	RT-PCR	 | 
| Vector free reprogramming | |
| Type of used vector free reprogramming factor(s) | 
	None	 | 
| Other | |
| Derived under xeno-free conditions | No | 
| Derived under GMP? | No | 
| Available as clinical grade? | No | 
Culture Conditions
| Surface coating | Matrigel/Geltrex | 
| Feeder cells | No | 
| Passage method | Enzymatically 
											Accutase										 | 
| O2 Concentration | 5 % | 
| CO2 Concentration | 5 % | 
| Medium | Other medium: 
			Base medium: DMEM/F12: FTDA medium			 Main protein source: Albumine Serum concentration: 0 % | 
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes | 
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes | 
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes | 
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| SSEA-3 | Yes |  | ||||
| NANOG | Yes |  | 
						SSEA-3: over 90%						
						Differentiation Potency
| Microbiology / Virus Screening | |
| HIV 1 | Negative | 
| Hepatitis B | Negative | 
| Mycoplasma | Negative | 
Genotyping
| Karyotyping (Cell Line) | |
| Has the cell line karyotype been analysed? | Yes 
												46, XX
											 
											Passage number: p32											 
											Karyotyping method:
											NanoString nCounter® human karyotype panel											
																						 | 
| Other Genotyping (Cell Line) | |
Genetic Modification
| Disease/phenotype related modifications |  | 
| Genetic modifications not related to a disease |  | 

Login to share your feedback, experiences or results with the research community.